<div id="readability-page-1"><p>Savara, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Francois Brisebois from LifeSci Capital reiterated a Buy rating on the stock and has a $11.00 price target.</p><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Francois Brisebois has given his Buy rating due to a combination of factors tied to Savara’s lead asset, MOLBREEVI, and its regulatory momentum. He highlights the recent FDA Day 74 letter confirming no advisory committee and ongoing priority review of the BLA, alongside strong Phase 3 data showing statistically significant and durable efficacy in aPAP, which together underpin his high confidence in U.S. approval by the August 22, 2026 PDUFA date.</p> <p>He also underscores the parallel progress ex-U.S., with marketing applications now submitted to both the EMA and the U.K. regulator, positioning the drug for broader international uptake and reinforcing its commercial potential. Coupled with Savara’s solid balance sheet, current cash of roughly $236 million, and access to substantial non-dilutive capital upon approval, he views the company as well funded for launch execution and maintains an Outperform rating with meaningful upside to his $11 price target.</p> <p>According to TipRanks, Brisebois is a 2-star analyst with an average return of <span>0.1%</span> and a 38.26% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Opus Genetics, and Aquestive Therapeutics.</p> <p>In another report released on March 9, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.</p></div>

SBIO

SVRA

LABU

<p>Savara received a Buy rating from analyst Francois Brisebois of LifeSci Capital, who set a price target of $11. The rating is supported by positive Phase 3 data for its lead asset, MOLBREEVI, and favorable regulatory developments, including a recent FDA letter confirming no advisory committee and ongoing priority review. The company is well-positioned for international market uptake with applications submitted to the EMA and U.K. regulator, and has a solid balance sheet with $236 million in cash. H.C. Wainwright also maintains a Buy rating with a $10 target.</p>

- Savara, a healthcare company, was recently reassessed by Wall Street analyst Francois Brisebois from LifeSci Capital, who reaffirmed a buy rating with a target price of $11.00.  
- This rating is based on favorable factors related to Savara's main asset, MOLBREEVI, including recent FDA communications and strong Phase 3 data, leading to confidence in the upcoming PDUFA date for U.S. approval.  
- Brisebois also noted the company's robust balance sheet and parallel progress in international regulatory applications, which enhances its commercial potential.

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

SPDR S&P Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

Savara

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target